Head-to-head · WeighScore
Basal Health vs NowPatient
The verdict
NowPatient takes it — 65.5/100 to 47.7/100.
NowPatient grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Basal Health | NowPatient |
|---|---|---|
| WeighScore | 47.7/100 | 65.5/100 |
| Grade | C | C |
| Scorecard rank | #494 | #217 |
| Semaglutide | Not disclosed | $1,349/mo (brand Wegovy) |
| Tirzepatide | Not disclosed | $1,069/mo (brand Mounjaro, promotional rate) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #494 · C
Strengths
- Stated nationwide coverage (50 states + DC)
- Metabolic-framework positioning rather than single-product
- Clinician-supervised dosing rather than a fixed protocol
- Adaptive monitoring approach
Where it loses points
- No pricing shown publicly — you must complete intake to see cost
- Compounding pharmacy partner not named
- GLP-1 molecules not specified (semaglutide vs tirzepatide vs oral)
- No LegitScript badge visible on the homepage
- No FDA compounded-medication disclaimer on the pages reviewed
Graded #217 · C
Strengths
- Free telehealth consultation — you only pay for the medication
- Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
- One of the few platforms offering Wegovy in both injection and oral pill form
- No compounded options — every drug is FDA-approved brand-name
Where it loses points
- Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
- No compounded semaglutide or tirzepatide (usually the cheaper route)
- State availability determined during intake, not shown upfront
- Does not offer Foundayo (orforglipron)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.